ATRI derived analysis dataset.
Usage
data(SUBJINFO)
Details
SUBSTUDY: NA
BID: NA
TX: Random treatment assigment.
AGEYR: Age in years at Consent
MARITAL: Marital Status
SEX: Sex
RACE: Race
EDCCNTU: Years of education
ETHNIC: Ethnicity
WRKRET: Participant Retirement Status
TESTLNG: Language to be used for testing
SAMELNG: Testing and Primary Lang are the same
RESIDENCE: Type of Residence
DISCDTC_DAYS_CONSENT: Subject Discontinuation Date Character (Derived to days since study consent date)
DISCDTC_DAYS_T0: Subject Discontinuation Date Character (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
ENRLDT_DAYS_CONSENT: Enrollment Date (Derived to days since study consent date)
ENRLDT_DAYS_T0: Enrollment Date (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
RNDMDT_DAYS_CONSENT: Randomization Date (Derived to days since study consent date)
RNDMDT_DAYS_T0: Randomization Date (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
GDSSEVBL: Geriatric Depression Scale Score > 5
SUBJCOMPTR: Subj Completer Set - TR Phase
TRTENDT_DAYS_CONSENT: Treatment End Date (Derived to days since study consent date)
TRTENDT_DAYS_T0: Treatment End Date (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
TRTSTDT_DAYS_CONSENT: Treatment Start Date (Derived to days since study consent date)
TRTSTDT_DAYS_T0: Treatment Start Date (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
TRTESDT_DAYS_CONSENT: Treatment Escalation Date: Date of the first visit participant started high dose (800 mg or 1600 mg) (Derived to days since study consent date)
TRTESDT_DAYS_T0: Treatment Escalation Date: Date of the first visit participant started high dose (800 mg or 1600 mg) (Derived to days since study start date [A4: Ranomization date | LEARN: Baseline registry exam date])
TRTESVIS: Treatment Escalation Visit: First visit participant started high dose (800 mg or 1600 mg)
HGTCMBL: Height in Cm at Baseline
WGTKGBL: Weight in Kg at Baseline
BMIBL: body mass index (weight (kg) / [height (m)]^2)
ALCHLBL: Current Alcohol Consumer at Baseline
CFBL: Current Caffeine User at Baseline
TBBL: Current Tobacco User at Baseline
COGDSSTTSV1: DSST Total Score at Visit 1
COGDSSTTSV6: DSST Total Score at Visit 6
COGLMDRTSV1: LM Delayed Recall Total Score at Visit 1
COGLMDRTSV6: LM Delayed Recall Total Score at Visit 6
COGTOTRECSV1: Total Recall Score at Visit 1
COGTOTRECSV6: Total Recall Score at Visit 6
MMSETSV1: MMSE Total Score at Visit 1
MMSETSV6: MMSE Total Score at Visit 6
PACCV6: PACC Total Score at Visit 6
APOEGN: APOE4 genotype (ε2/ε4, ε3/ε4, ε4/ε4, no ε4)
APOEGNPRSNFLG: APOE4 carrier status (carrier [ε2/ε4, ε3/ε4, ε4/ε4], noncarrier [ε3/ε3, ε2/ε2,ε3/ε2])
AAPOEGNPRSNFLG: APOE4 carrier status used for analysis. If APOEGNPRSNFLG is missing, carrier status is assumed to be noncarrier as in the randomization plan.
SUVRCER: Amyloid PET composite SUVR
AMYLCENT: Amyloid PET centiloids. AMYLCENT = 183.07 x SUVRCER – 177.26.
SUBJITTTR: Subj Intent to Treat Set - TR Phase
MITTFL: Modified Intent-to-Treat Flag
SUBJSAFTR: Safety Population Flag
PCCPFL: Placebo-Controlled Completers Population Flag
PRTVIIE: Protocol Violation - Eligibility Criteria Flag
PRTVIMAS: Protocol Violation - Missed ADCS-PACC Flag
CON3FL: Protocol Violation - Missed Consecutive Infusions
PRTVITMS: Protocol Violation - Missed Infusions
PPTRTDUR: Treatment Duration >240wk for Completers Flag
SUBJPPSTR: Subj Per Protocol Set - TR Phase
LEARNFL: LEARN Participant Flag
TAUPETFL: Tau PET (Flortaucipir) Participant Flag
FRAMINGHAM: Framingham Risk Score
RESCREENFL: Rescreened Participant Flag
PREVBID: Previous BID if previously screened
Examples
if (FALSE) { # \dontrun{
browseVignettes('A4LEARN')
} # }